Genelux Corp (GNLX): Revenue
$8.0K
Year ended 2025-12-31
-91.0%
3-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.0K | 0.0% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $8.0K | -95.3% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $170.0K | -98.5% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $11.07M | n/a | 2024-03-29, From 2022-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Genelux Corp (GNLX) | 2025-12-31 | $8.0K | 0.0% |
| Aspire-Lakewood Holdings, Inc. (ASBP) | 2025-12-31 | $6.2K | n/a |
| Alaunos Therapeutics, Inc. (TCRT) | 2025-12-31 | $5.0K | -50.0% |
| One World Products, Inc. (OWPC) | 2024-12-31 | $4.9K | -35.9% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $17.0K | n/a |
| Bioadaptives, Inc. (BDPT) | 2025-12-31 | $18.3K | +44.3% |
| Skinvisible, Inc. (SKVI) | 2025-12-31 | $20.0K | 0.0% |
| Aditxt, Inc. (ADTX) | 2025-12-31 | $3.2K | -97.6% |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | $21.8K | n/a |
Compare GNLX, ASBP, TCRT, OWPC side by side · Screen every company in Pharmaceutical Preparations ↗